MedTrace Logo

A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix

NCT00193804 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-09-16

No results posted yet for this study

Summary

A study to evaluate the efficacy of Intensity Modulated Radiation Therapy (IMRT) as compared to Standard Conventional Radiotherapy Alone in the treatment of carcinoma cervix. Concomitant Weekly Cisplatin chemotherapy will be given as a routine, which is a standard of care today for early stage cervical cancers including stage IIB. The benefits of using IMRT in reducing radiation-induced toxicity are well known. Since this treatment modality has not yet been validated and studied in a randomized trial setting, the present study is being undertaken. The study arm of IMRT has the potential to reduce the toxicities by 15-20%, but is associated with labor intense procedure requiring many hospital visits before actual start of treatment.

Conditions

  • Cancer of Cervix

Interventions

RADIATION

IMRT

IMRT in cervical cancers

Sponsors & Collaborators

  • Varian Medical Systems

    collaborator INDUSTRY

  • Tata Memorial Hospital

    lead OTHER_GOV

Principal Investigators

  • Shyamkishore J Shrivastava, MD, DNB (RT) · Professor & Head, Radiation Oncology, Tata Memorial Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2017-06-20
Completion
2019-06-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00193804 on ClinicalTrials.gov